Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19

Investigational treatments/drugs for coronavirus disease 2019 (COVID-19) have been applied, with repurposed or newly developed drugs, and their effectiveness has been evaluated. Some of these drugs may be hepatotoxic, and each monotherapy or combination therapy may increase the risk of drug-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Ken, Yamazaki, Yuichi, Uraoka, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717018/
https://www.ncbi.nlm.nih.gov/pubmed/35068875
http://dx.doi.org/10.3748/wjg.v27.i48.8370
_version_ 1784624446223417344
author Sato, Ken
Yamazaki, Yuichi
Uraoka, Toshio
author_facet Sato, Ken
Yamazaki, Yuichi
Uraoka, Toshio
author_sort Sato, Ken
collection PubMed
description Investigational treatments/drugs for coronavirus disease 2019 (COVID-19) have been applied, with repurposed or newly developed drugs, and their effectiveness has been evaluated. Some of these drugs may be hepatotoxic, and each monotherapy or combination therapy may increase the risk of drug-induced liver injury (DILI). We should aim to control dysregulation of liver function, as well as the progression of COVID-19, as much as possible. We discussed the potential risks of investigational treatments/drugs and promising drugs for both COVID-19 and DILI due to investigational treatments/drugs.
format Online
Article
Text
id pubmed-8717018
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87170182022-01-20 Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19 Sato, Ken Yamazaki, Yuichi Uraoka, Toshio World J Gastroenterol Letter to the Editor Investigational treatments/drugs for coronavirus disease 2019 (COVID-19) have been applied, with repurposed or newly developed drugs, and their effectiveness has been evaluated. Some of these drugs may be hepatotoxic, and each monotherapy or combination therapy may increase the risk of drug-induced liver injury (DILI). We should aim to control dysregulation of liver function, as well as the progression of COVID-19, as much as possible. We discussed the potential risks of investigational treatments/drugs and promising drugs for both COVID-19 and DILI due to investigational treatments/drugs. Baishideng Publishing Group Inc 2021-12-28 2021-12-28 /pmc/articles/PMC8717018/ /pubmed/35068875 http://dx.doi.org/10.3748/wjg.v27.i48.8370 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Sato, Ken
Yamazaki, Yuichi
Uraoka, Toshio
Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title_full Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title_fullStr Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title_full_unstemmed Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title_short Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
title_sort strategy for the control of drug-induced liver injury due to investigational treatments/drugs for covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717018/
https://www.ncbi.nlm.nih.gov/pubmed/35068875
http://dx.doi.org/10.3748/wjg.v27.i48.8370
work_keys_str_mv AT satoken strategyforthecontrolofdruginducedliverinjuryduetoinvestigationaltreatmentsdrugsforcovid19
AT yamazakiyuichi strategyforthecontrolofdruginducedliverinjuryduetoinvestigationaltreatmentsdrugsforcovid19
AT uraokatoshio strategyforthecontrolofdruginducedliverinjuryduetoinvestigationaltreatmentsdrugsforcovid19

Ejemplares similares